Cochrane Review Confirms Convalescent Plasma Fails to Cut COVID-19 Mortality
A landmark 48-RCT Cochrane review finds high-certainty evidence that convalescent plasma does not reduce death in moderate-to-severe COVID-19.
Summary
This updated Cochrane systematic review pooled data from 48 randomized controlled trials involving over 24,500 people with COVID-19. For those with moderate to severe disease, high-certainty evidence shows convalescent plasma does not reduce deaths, prevent mechanical ventilation, or improve hospital discharge rates compared to standard care or placebo. For mild disease, the evidence remains uncertain, though moderate-certainty evidence suggests convalescent plasma may reduce hospitalizations or death compared to standard plasma. The authors characterize CP as probably having little to no effect on serious adverse events versus placebo (moderate certainty). They conclude this research question is no longer a priority, as new studies are publishing less frequently and findings are unlikely to shift the conclusions. The review was previously maintained as a living systematic review from its first version in 2020 through the October 2024 search.
Detailed Summary
During the COVID-19 pandemic, convalescent plasma — blood plasma from recovered patients containing antibodies — was rapidly deployed as a potential therapy before robust evidence existed. Understanding whether it actually works, and for whom, became a critical clinical question.
This Cochrane systematic review, now in its seventh edition, synthesized data from 48 randomized controlled trials enrolling 24,518 participants. Studies were searched through October 2024. Outcomes assessed included all-cause mortality at 28 days, clinical worsening or improvement, hospital admission, symptom resolution, quality of life, and adverse events, graded using the GRADE evidence framework.
For moderate to severe COVID-19 — the largest and most clinically relevant subgroup — high-certainty evidence demonstrates convalescent plasma does not reduce 28-day mortality (RR 0.96, 95% CI 0.90–1.03; 31 RCTs, 20,798 participants). It also shows little to no impact on invasive mechanical ventilation or death, and no effect on hospital discharge rates. Moderate-certainty evidence indicates convalescent plasma probably has little to no effect on serious adverse events versus placebo (RR 1.19, 95% CI 1.02–1.38; 11 studies, 5,298 participants). For mild disease, results are mostly uncertain, but moderate-certainty evidence suggests convalescent plasma compared to standard plasma probably reduces hospital admission or death (RR 0.50, 95% CI 0.32–0.78; 2 RCTs, 1,597 participants).
The practical implication is clear: convalescent plasma should not be used routinely for moderate or severe COVID-19. It offers no survival benefit. The mild-disease finding is intriguing but limited by very few trials and low participant numbers.
Important caveats include variability in antibody titers of plasma used, timing of administration, and disease severity at enrollment across trials. Summary is based on the abstract only, as the full text was not accessible.
Key Findings
- High-certainty evidence: convalescent plasma does not reduce 28-day mortality in moderate-to-severe COVID-19 (RR 0.96, 95% CI 0.90–1.03).
- No effect on mechanical ventilation, death, or hospital discharge in severe disease across ~20,798 participants (high certainty).
- Moderate-certainty evidence: convalescent plasma probably has little to no effect on serious adverse events versus placebo (RR 1.19, 95% CI 1.02–1.38).
- In mild COVID-19, convalescent plasma vs. standard plasma probably reduces hospital admission or death (RR 0.50, 95% CI 0.32–0.78; moderate certainty).
- Authors conclude this is no longer a priority research question; new studies are unlikely to change conclusions.
Methodology
Cochrane systematic review and meta-analysis of 48 RCTs (24,518 participants) searched through October 2024 across CENTRAL, MEDLINE, Embase, and clinical trial registries. Risk of bias was assessed using RoB 2; certainty of evidence rated with the GRADE approach. Subgroup analyses examined antibody levels, symptom onset timing, income level, and comorbidities.
Study Limitations
Summary is based on the abstract only, as the full review text was not accessible; detailed subgroup and sensitivity analyses could not be evaluated. Heterogeneity in plasma antibody titers, timing of treatment, and patient populations across trials may limit the generalizability of pooled estimates. Evidence for mild disease remains very uncertain due to limited trial numbers and participant counts.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.